EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis

Elena Baez, Mette Gyldenløve, Hakim Ben Abdallah, Thomas Emmanuel, Jennifer Astrup Sørensen, Simon Francis Thomsen, Claus Zachariae, Alexander Egeberg, Lone Skov, Lars Iversen, Claus Johansen

Journal of Investigative Dermatology · 2025

DOI: 10.1016/j.jid.2025.04.034 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Elena Baez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electron…. Hauptthemen laut MEDLINE: Aminopyridines, Benzamides, CD4-Positive T-Lymphocytes, Cytokines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Simon Spies Fonden, Kongelig Hofbuntmager Aage Bangs Fond, Danmarks Grundforskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the treatment of chronic obstructive pulmonary disease. In a recent clinical trial, oral roflumilast demonstrated clinical efficacy and safety in psoriasis, but the underlying mechanisms in skin have not previously been studied. This substudy investigated the cellular and molecular effects of oral roflumilast treatment on psoriatic skin in vivo. In the PSORRO (Psoriasis Treatment with Oral Roflumilast) study, patients with moderate-to-severe plaque psoriasis were randomized 1:1 to monotherapy with 500 μg oral roflumilast once daily or placebo (ClinicalTrials.gov NCT04549870). Skin punch biopsies from 24 patients were obtained at baseline, week 4, and week 12 for RNA sequencing and quantitative immunohistochemistry. At week 12, genes encoding proinflammatory mediators (eg, CXCL1, CXCL8, IL1B, IL17A, IL23A, and IL36A) were significantly downregulated in patients treated with oral roflumilast compared with that in those treated with placebo. The gene signatures and histologic infiltration of several immune cell populations were also downregulated, most significantly for CD4+ T cells and neutrophils. The epidermal thickness of lesional skin decreased by 32% from baseline, compared with a 7% decrease in the placebo group. Our findings suggest that oral roflumilast downregulates numerous key proinflammatory gene and histologic biomarkers, supporting its potential as a systemic treatment for psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesBenzamidesCD4-Positive T-LymphocytesCytokinesNeutrophil InfiltrationPhosphodiesterase 4 InhibitorsPsoriasisAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralBiopsyCyclopropanesDouble-Blind MethodSignal TransductionSkinTreatment Outcome

Stichwörter der Autor:innen

Gene expressionInflammationPDE4 inhibitorPsoriasisRoflumilast

Substanzen

AminopyridinesBenzamidesCyclopropanesCytokinesPhosphodiesterase 4 InhibitorsRoflumilast

Autor:innen und Institutionen

  • Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: 201810081@post.au.dk.
  • Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Dermatology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Dermatology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Förderung

  • Simon Spies Fonden
  • Kongelig Hofbuntmager Aage Bangs Fond
  • Danmarks Grundforskningsfond

Zitieren

APA

Baez, E., Gyldenløve, M., Ben Abdallah, H., Emmanuel, T., Sørensen, J. A., Thomsen, S. F., Zachariae, C., Egeberg, A., Skov, L., Iversen, L., & Johansen, C. (2025). Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2025.04.034

Vancouver

Baez E, Gyldenløve M, Ben Abdallah H, Emmanuel T, Sørensen JA, Thomsen SF, et al. Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2025.04.034

BibTeX
@article{Baez2025,
  author = {Baez, Elena and Gyldenløve, Mette and Ben Abdallah, Hakim and Emmanuel, Thomas and Sørensen, Jennifer Astrup and Thomsen, Simon Francis and Zachariae, Claus and Egeberg, Alexander and Skov, Lone and Iversen, Lars and Johansen, Claus},
  title = {Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis},
  journal = {Journal of Investigative Dermatology},
  year = {2025},
  doi = {10.1016/j.jid.2025.04.034}
}
Kostenlos starten →